IL325099A - Oral solid estrogen receptor antagonist dosage forms - Google Patents
Oral solid estrogen receptor antagonist dosage formsInfo
- Publication number
- IL325099A IL325099A IL325099A IL32509925A IL325099A IL 325099 A IL325099 A IL 325099A IL 325099 A IL325099 A IL 325099A IL 32509925 A IL32509925 A IL 32509925A IL 325099 A IL325099 A IL 325099A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- tablet
- dosage form
- oral dosage
- polyethylene glycol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363472523P | 2023-06-12 | 2023-06-12 | |
| PCT/US2024/033417 WO2024258856A1 (fr) | 2023-06-12 | 2024-06-11 | Formes posologiques orales solides d'agents de dégradation des récepteurs des œstrogènes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL325099A true IL325099A (en) | 2026-02-01 |
Family
ID=91738206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL325099A IL325099A (en) | 2023-06-12 | 2024-06-11 | Oral solid estrogen receptor antagonist dosage forms |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4724045A1 (fr) |
| JP (1) | JP2026522318A (fr) |
| KR (1) | KR20260022394A (fr) |
| CN (1) | CN121311218A (fr) |
| AU (1) | AU2024303588A1 (fr) |
| IL (1) | IL325099A (fr) |
| MX (1) | MX2025014795A (fr) |
| TW (1) | TW202500155A (fr) |
| WO (1) | WO2024258856A1 (fr) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| AU2010223105B2 (en) | 2009-03-09 | 2016-05-12 | Spi Pharma, Inc. | Highly compactable and durable direct compression excipients and excipient systems |
| MX376083B (es) * | 2015-06-04 | 2025-03-07 | Pfizer | Formas de dosificacion solidas de palbociclib. |
| IL266842B (en) | 2016-12-01 | 2022-09-01 | Arvinas Operations Inc | History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists |
| WO2021041348A1 (fr) | 2019-08-26 | 2021-03-04 | Arvinas Operations, Inc. | Procédés de traitement du cancer du sein avec des dérivés de tétrahydronaphtalène en tant qu'agents de dégradation du récepteur des œstrogènes |
| AU2021342287A1 (en) * | 2020-09-14 | 2023-04-13 | Arvinas Operations, Inc. | Crystalline forms of a compound for the targeted degradation of estrogen receptor |
| JP2025512788A (ja) * | 2022-03-25 | 2025-04-22 | シェンチェン ファーマシン シーオー.,エルティーディー. | Protac化合物の医薬組成物及びその使用 |
-
2024
- 2024-06-11 WO PCT/US2024/033417 patent/WO2024258856A1/fr not_active Ceased
- 2024-06-11 IL IL325099A patent/IL325099A/en unknown
- 2024-06-11 KR KR1020267000497A patent/KR20260022394A/ko active Pending
- 2024-06-11 JP JP2025571587A patent/JP2026522318A/ja active Pending
- 2024-06-11 CN CN202480038499.7A patent/CN121311218A/zh active Pending
- 2024-06-11 TW TW113121509A patent/TW202500155A/zh unknown
- 2024-06-11 AU AU2024303588A patent/AU2024303588A1/en active Pending
- 2024-06-11 EP EP24737275.8A patent/EP4724045A1/fr active Pending
-
2025
- 2025-12-08 MX MX2025014795A patent/MX2025014795A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2025014795A (es) | 2026-01-07 |
| WO2024258856A1 (fr) | 2024-12-19 |
| TW202500155A (zh) | 2025-01-01 |
| AU2024303588A1 (en) | 2025-12-18 |
| EP4724045A1 (fr) | 2026-04-15 |
| CN121311218A (zh) | 2026-01-09 |
| KR20260022394A (ko) | 2026-02-19 |
| JP2026522318A (ja) | 2026-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5835883B2 (ja) | 被覆錠剤製剤 | |
| JP5801826B2 (ja) | ダビガトランエテキシラートを含有する経口用医薬組成物 | |
| KR20150097792A (ko) | 개선된 생체이용률을 갖는 약학 조성물 | |
| WO2012164578A1 (fr) | Compositions et procédés de préparation de formulations de nilotinib à libération immédiate | |
| JP7648698B2 (ja) | 難溶性の塩基性薬剤を含有する医薬組成物 | |
| WO2015124995A1 (fr) | Formes galéniques solides de rivaroxaban | |
| EP3620156A1 (fr) | Composition ayant une solubilité dans l'eau et une biodisponibilité améliorées | |
| US20140319720A1 (en) | Pharmaceutical compositions comprising rivaroxaban | |
| KR101479824B1 (ko) | 용출 안정성 제제 | |
| NZ760233A (en) | Compositions and methods for treatment of abnormal cell growth | |
| JP5635491B2 (ja) | 固形医薬組成物 | |
| JP5769362B2 (ja) | 圧縮製剤 | |
| TWI624275B (zh) | 具有高含量菲索芬那定(fexofenadine)之固態單位及其製備方法 | |
| EP2540294A1 (fr) | Préparation solide à libération prolongée pour usage oral | |
| KR101171375B1 (ko) | 난용성 약물을 함유하는 경구 제형 | |
| EP1959934A2 (fr) | Comprime bicouche comprenant du telmisartan et un diuretique | |
| US20130085145A1 (en) | Imatinib mesilate pharmaceutical tablet | |
| US20090030057A1 (en) | Pharmaceutical composition of telmisartan | |
| EP4724045A1 (fr) | Formes posologiques orales solides d'agents de dégradation des récepteurs des ?strogènes | |
| US11260055B2 (en) | Oral pharmaceutical composition of lurasidone and preparation thereof | |
| KR101944085B1 (ko) | 발사르탄 함유 고형 경구제형 및 그 제조방법 | |
| CN112057427A (zh) | 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法 | |
| EP4729048A1 (fr) | Comprimés d'oxazépam à dispersion orale | |
| WO2026019402A1 (fr) | Composition pharmaceutique comprenant une nanosuspension de canagliflozine | |
| CN116492305A (zh) | 一种盐酸洛氟普啶片及其制备方法 |